Beam Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Depreciation & Amortization Growth & History (BEAM)
Beam Therapeutics's depreciation and amortization was $22.3M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $22.3M | $369,000 | +1.68% |
| 2024 | 2024-12-31 | $21.9M | $1.9M | +9.56% |
| 2023 | 2023-12-31 | $20.0M | $5.9M | +41.46% |
| 2022 | 2022-12-31 | $14.1M | $6.7M | +89.87% |
| 2021 | 2021-12-31 | $7.5M | $2.7M | +57.36% |
| 2020 | 2020-12-31 | $4.7M | $1.2M | +35.17% |
| 2019 | 2019-12-31 | $3.5M | — | — |
Beam Therapeutics quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.4M | −$128,000 | −2.31% |
| Q1 2026 | 2026-03-31 | $5.6M | $77,000 | +1.39% |
| Q4 2025 | 2025-12-31 | $5.7M | — | — |
| Q3 2025 | 2025-09-30 | $5.6M | $85,000 | +1.55% |
| Q2 2025 | 2025-06-30 | $5.5M | −$38,000 | −0.68% |
| Q1 2025 | 2025-03-31 | $5.5M | $97,000 | +1.79% |
| Q3 2024 | 2024-09-30 | $5.5M | $288,000 | +5.55% |
| Q2 2024 | 2024-06-30 | $5.6M | $760,000 | +15.78% |
| Q1 2024 | 2024-03-31 | $5.4M | $784,000 | +16.87% |
| Q3 2023 | 2023-09-30 | $5.2M | $1.7M | +49.35% |
| Q2 2023 | 2023-06-30 | $4.8M | $1.4M | +40.90% |
| Q1 2023 | 2023-03-31 | $4.6M | $1.3M | +40.31% |
| Q3 2022 | 2022-09-30 | $3.5M | $1.7M | +98.46% |
| Q2 2022 | 2022-06-30 | $3.4M | $1.7M | +104.79% |
| Q1 2022 | 2022-03-31 | $3.3M | $1.9M | +136.91% |
| Q3 2021 | 2021-09-30 | $1.8M | $532,000 | +43.68% |
| Q2 2021 | 2021-06-30 | $1.7M | $524,000 | +45.76% |
| Q1 2021 | 2021-03-31 | $1.4M | $298,000 | +27.09% |
| Q3 2020 | 2020-09-30 | $1.2M | $310,000 | +34.14% |
| Q2 2020 | 2020-06-30 | $1.1M | $287,000 | +33.45% |
| Q1 2020 | 2020-03-31 | $1.1M | $365,000 | +49.66% |
| Q3 2019 | 2019-09-30 | $908,000 | — | — |
| Q2 2019 | 2019-06-30 | $858,000 | — | — |
| Q1 2019 | 2019-03-31 | $735,000 | — | — |
Beam Therapeutics depreciation and amortization trends
Over the last five fiscal years, Beam Therapeutics's depreciation and amortization increased from $4.7M to $22.3M, a change of $17.6M. The latest reported quarter, Q2 2026, shows $5.4M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...